ArticleMolecular medicine reports2019
MicroRNA‑155 inhibits the proliferation of CD8+ T cells via upregulating regulatory T cells in vitiligo.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Role of miR-155 in inflammatory autoimmune diseases: a comprehensive review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Pooled it
- Meta-Analysis of Alterations in Regulatory T Cells' Frequency and Suppressive Capacity in Patients with Vitiligo.Journal of immunology research · 2022Pooled it
- Epigenetic reprogramming in autoimmune and immune-mediated skin disease.Frontiers in immunology · 2026Review
- Epigenetic Modifications in Vitiligo.Clinical reviews in allergy & immunology · 2025Review
- The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Analysis of granulysin expression in vitiligo and halo-nevus.Scientific reports · 2024Article
- Expression Signature of Immune-Related MicroRNAs in Autoimmune Skin Disease: Psoriasis and Vitiligo Insights.Molecular diagnosis & therapy · 2023Article
- Expression Profile and Bioinformatics Analysis of Circular RNAs in Patients with Vitiligo.Pharmacogenomics and personalized medicine · 2022Article
- Differential Expression of Serum Exosomal Hsa-miR-487b-3p in Progressive Vitiligo Before and After Systemic Corticosteroid Treatment.Clinical, cosmetic and investigational dermatology · 2022Article
- Emerging Role of Non-Coding RNAs in Regulation of T-Lymphocyte Function.Frontiers in immunology · 2021Review
- MicroRNA‑21‑5p protects melanocytes via targeting STAT3 and modulating Treg/Teff balance to alleviate vitiligo.Molecular medicine reports · 2021Article
- Current insight into the roles of microRNA in vitiligo.Molecular biology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported that loss and degradation of epidermal melanocytes is closely associated with the pathogenesis of vitiligo. In addition, CD8+ T and regulatory T (Treg) cells serve an important role during these two processes. MicroRNA‑155 (miR‑155) is known to contribute to the pathogenesis of vitiligo; however, the mechanism by which miR‑155 regulates the development of vitiligo remains unclear. In the present study, naïve T and CD8+ T cells were isolated from a patient with non‑segmental vitiligo by flow cytometry. The cells were differentiated into Treg cells by treatment with interleukin‑2, transforming growth factor‑β and retinoic acid. In addition, miR‑155 agonists and antagonists were used to investigate the effect of miR‑155 on the proliferation of CD8+ T cells, Treg cells and melanocytes. The results demonstrated that the miR‑155 agonist significantly decreased the rate of CD8+ T cell growth, as well as promoted the proliferation of melanocytes by inducing an increase in the percentage of Treg cells. By contrast, the miR‑155 antagonist inhibited the proliferation of melanocytes by decreasing the percentage of Treg cells. miR‑155 protected melanocyte survival by increasing the number of Treg cells and by decreasing the number of CD8+ T cells. Therefore, these data may provide a new prospect for the treatment of vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.